| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| ln Vivo |
Renal 17-ODYA (0.28 mg/kg; intracoronary; infusion over 2 to 3 minutes; dog) significantly inhibits 20-HETE production during local reperfusion and produces a significant reduction in myocardial infarction. This is associated with increased renal papillary blood flow, renal blood flow, and renal small blood flow when infusion of 17-ODYA (16.5 nmol/min) directly into the renal interstitium of the kidney causes diuresis and natriuresis [3].
|
|---|---|
| Animal Protocol |
Adult mongrel dogs of either sex weighing 15-25 kg were used. Dogs were anesthetized with pentobarbital (30 mg/kg intravenously), intubated, and ventilated with room air supplemented with oxygen. A left thoracotomy was performed at the fifth intercostal space, and the heart was suspended in a pericardial cradle. The left anterior descending coronary artery was isolated distal to the first diagonal branch for later occlusion. Catheters were placed in the aorta for blood pressure measurement and blood sampling, in the left atrium for microsphere injection, and in the great cardiac vein for venous blood sampling. Dogs were randomly assigned to treatment groups. Fifteen minutes before the 60-minute LAD occlusion period, 17-ODYA (0.07 or 0.28 mg/kg) or vehicle was administered by intracoronary infusion over 2-3 minutes. Hemodynamic measurements, blood gas analyses, and myocardial blood flow measurements were performed at baseline and at 30 minutes into the occlusion period. After 60 minutes of occlusion, the LAD was reperfused for 3 hours. At the end of reperfusion, hearts were electrically fibrillated, removed, and prepared for infarct size determination and regional myocardial blood flow measurement [3].
For infarct size determination, the LAD was cannulated. Five mL of Patent blue dye and 5 mL saline were injected at equal pressure into the left atrium and LAD, respectively, to determine the area at risk and nonischemic area. The left ventricle was sliced into serial transverse sections 6-7 mm thick. The nonstained ischemic area and blue-stained normal area were separated and incubated with 1% triphenyltetrazolium chloride in 0.1 mol/L phosphate buffer (pH 7.4) at 37°C for 15 minutes. After overnight incubation in 10% formaldehyde, noninfarcted and infarcted tissues within the area at risk were separated and weighed. Infarct size was expressed as a percentage of the area at risk [3]. |
| References |
|
| Additional Infomation |
Octadec-17-ynoic acid is an alkyne fatty acid formed by the didehydrogenation reaction of octadecanoic acid (stearic acid) at positions 17 and 18. It functions as a P450 inhibitor, an EC 1.14.14.94 (leukotriene B4 20-monooxygenase) inhibitor, and an EC 1.14.15.3 (alkane 1-monooxygenase) inhibitor. It is a long-chain fatty acid, an alkyne fatty acid, a terminal alkyne compound, and a monounsaturated fatty acid.
|
| Molecular Formula |
C18H32O2
|
|---|---|
| Molecular Weight |
280.44548
|
| Exact Mass |
280.24
|
| CAS # |
34450-18-5
|
| PubChem CID |
1449
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
400.8±18.0 °C at 760 mmHg
|
| Melting Point |
142-148 °C(lit.)
|
| Flash Point |
194.7±15.9 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.470
|
| LogP |
6.86
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
20
|
| Complexity |
262
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DZIILFGADWDKMF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h1H,3-17H2,(H,19,20)
|
| Chemical Name |
octadec-17-ynoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~89.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (8.91 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5657 mL | 17.8285 mL | 35.6570 mL | |
| 5 mM | 0.7131 mL | 3.5657 mL | 7.1314 mL | |
| 10 mM | 0.3566 mL | 1.7828 mL | 3.5657 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
